Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
• Source: Shutterstock

Ahead of planned completion in June, German developer Formycon has published positive preliminary efficacy and safety data from its MAGELLAN-AMD Phase III clinical trial comparing the company’s proposed FYB203 aflibercept biosimilar to Regeneron’s Eylea (aflibercept) reference product.

Involving 434 participants, the randomized, double-masked, multicenter study is comparing the efficacy and safety of FYB203 to the world’s leading...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products